[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Previous Issue
Volume 5, December
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 

Hemato, Volume 6, Issue 1 (March 2025) – 1 article

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Section
Select all
Export citation of selected articles as:
14 pages, 1217 KiB  
Article
Hematological Side Effects of 177Lu-DOTA-TATE Therapy in Patients with NENs
by Luciano Carideo, Rosaria Meucci, Giuseppe Campagna, Vincenzo Marcello Russo, Enrico D’Ippolito, Maria Rinzivillo, Francesco Panzuto and Daniela Prosperi
Hemato 2025, 6(1), 1; https://doi.org/10.3390/hemato6010001 - 30 Dec 2024
Viewed by 323
Abstract
Background/Objectives: Lutathera® ([177Lu]Lu-DOTA-TATE) is the first radiolabelled somatostatin (SST) analog approved for the treatment of patients with well-differentiated (G1 and G2) unresectable or metastatic gastro-entero-pancreatic neuro-endocrine-neoplasms (GEP-NENs). The bone marrow and kidneys are critical organs for RLT with [ [...] Read more.
Background/Objectives: Lutathera® ([177Lu]Lu-DOTA-TATE) is the first radiolabelled somatostatin (SST) analog approved for the treatment of patients with well-differentiated (G1 and G2) unresectable or metastatic gastro-entero-pancreatic neuro-endocrine-neoplasms (GEP-NENs). The bone marrow and kidneys are critical organs for RLT with [177Lu]Lu-DOTA-TATE. Our purpose was to evaluate hematological and renal toxicity in 29 patients (18 males, 11 females) treated with Lutathera®. Methods: According to standard protocols, four cycles of (177Lu)Lu-DOTA-TATE were administered every eight/nine weeks. Patients received pre-medication with anti-emetic and anti-acid drugs and a slow amino acid infusion for renal protection. Blood count and serum creatinine data were collected at three time points: before the first cycle, after the second cycle, and at the end of treatment. Results: We found that almost all hematological parameters significantly decreased between the baseline and/or interim and post-therapy evaluation, although without a clinical impact. The presence of total tumor load or bone metastases had no influence on these findings, while male patients showed less hematological toxicity than females. Conversely, creatinine levels did not vary during treatment. Conclusions: Our study confirms that [177Lu]Lu-DOTATATE RLT is safe and well tolerated despite some minor (grade 1) hematological toxicity. Full article
(This article belongs to the Section Radiolabeled Blood Elements and Other Imaging Modalities)
Show Figures

Figure 1

Figure 1
<p>Trend of red blood cells in 29 patients.</p>
Full article ">Figure 2
<p>Trend of platelet count in 29 patients.</p>
Full article ">Figure 3
<p>Trend of white blood cells in 29 patients.</p>
Full article ">
Previous Issue
Back to TopTop